Patel Chintu 4/A

What Happened Chintu Patel, Co-CEO and director of Amneal Pharmaceuticals (AMRX), was granted a performance-based restricted stock unit (RSU) award representing up to 544,663 shares on March 2, 2026. The award is a derivative compensation grant (reported at $0.00 per share) and the filing on March 27, 2026 is an amendment correcting the original March 3, 2026 Form 4 to clarify that 100% of the grant consists of performance-based RSUs.

Key Details

• Transaction date: March 2, 2026 (Period of Report). Amended Form 4 filed March 27, 2026; original Form 4 filed March 3, 2026.
• Transaction type/code: Award/Acquisition (A) — derivative grant of performance-based RSUs.
• Reported amount: 544,663 performance-based RSUs (reported as the maximum possible shares).
• Price: $0.00 (no cash paid by the insider for the award).
• Vesting/conditions: Units vest based on average closing price targets over a three-year performance period; payout may range from 0% to 200% of the target number. Any earned units vest in full on February 28, 2029.
• Shares owned after transaction: Not disclosed in this filing.
• Amendment note: This Form 4 corrects the Original Form 4, which had mistakenly reported non-performance RSUs; the entire grant is performance-based.

Context Performance-based RSUs are a form of compensation, contingent on meeting specified performance (stock-price) targets, and do not represent an immediate cash purchase or sale. Such grants are routine executive compensation and should not be interpreted alone as a direct bullish or bearish trading signal.